NEW YORK, December 11, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), Celldex Therapeutics, Inc. (NASDAQ: CLDX), PDL BioPharma, Inc. (NASDAQ: PDLI), Amedisys Inc. (NASDAQ: AMED), and Exelixis, Inc. (NASDAQ: EXEL). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Regeneron Pharmaceuticals, Inc. Research Report
On December 4, 2013, Regeneron Pharmaceuticals, Inc. (Regeneron) announced that the Company will host a webcast its presentation at the Oppenheimer 24th Annual Healthcare Conference on December 11, 2013. The Company informed that the presentation is scheduled for 10:05 a.m. ET which will be accessible through Regeneron's website, where an archived version of the presentation will also be available for 30 days. The Full Research Report on Regeneron Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Celldex Therapeutics, Inc. Research Report
On December 4, 2013, Celldex Therapeutics, Inc. (Celldex) announced the pricing of an underwritten public offering of 7 million shares of its common stock, offered at a price to the public of $24.50 per share for an aggregate offering of $171.5 million of common stock. According to Celldex, the Company expects the net proceeds from this offering to be approximately $162,725,000, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Celldex. The Company further informed that the underwriters have been granted a 30-day option to purchase up to an aggregate of 1,050,000 additional shares of common stock. The offering is expected to close on or about December 10, 2013, subject to customary closing conditions. The Full Research Report on Celldex Therapeutics, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
PDL BioPharma, Inc. Research Report
On December 4, 2013, PDL BioPharma, Inc. (PDL BioPharma) announced that the adjusted conversion rate for the - 3.75% Convertible Senior Notes due May 1, 2015 (May 2015 Notes), is c.159.9 shares of common stock per $1,000 principal amount or approximately $6.25 per share, effective December 3, 2013; and 2.875% Series 2012 Convertible Senior Notes due February 15, 2015 (Series 2012 Notes), is c.182.6 and shares of common stock per $1,000 principal amount or approximately $5.48 per share, effective December 3, 2013. The Company further reported that the conversion rate for the May 2015 Notes was previously c.157.4 shares of common stock per $1,000 principal amount of the May 2015 Notes, and the conversion rate for the Series 2012 Notes was previously c.179.8 shares of common stock per $1,000 principal amount of the Series 2012 Notes. The Full Research Report on PDL BioPharma, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Amedisys Inc. Research Report
On December 5, 2013, Amedisys Inc. (Amedisys) announced that Senior Vice President of Finance and Treasurer, Thomas J. Dolan, will present at the 24th Annual Oppenheimer Healthcare Conference in New York, NY on December 11, 2013. Amedisys informed that the presentation is set to begin at 8:55 a.m. ET, with a live webcast available at the Company's website. The Full Research Report on Amedisys Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Exelixis, Inc. Research Report
On December 2, 2013, Exelixis, Inc. (Exelixis) announced that it has initiated a phase 2 clinical trial comparing cabozantinib plus abiraterone and prednisone (abiraterone/prednisone) versus abiraterone/prednisone in patients with castration-resistant prostate cancer (CRPC) who have bone metastases and have not been previously treated with chemotherapy. Exelixis reported that the primary endpoint for the randomized, open-label trial is radiographic progression-free survival (PFS). The Company informed that the phase 2 trial will compare abiraterone/prednisone against abiraterone/prednisone in combination with one of the three cabozantinib doses: 40 mg daily, 20 mg daily, or 20 mg every other day. The Company expects that the trial to enroll 280 chemotherapy-naïve CRPC patients who have bone metastases, and will be conducted at approximately 50 sites in North America. The Company further informed that in addition to evaluating radiographic PFS, the trial includes pre-specified outcome measures of safety and tolerability, pharmacokinetics of cabozantinib in combination with abiraterone, overall survival (OS), and bone scan response by computer-aided detection. The Full Research Report on Exelixis, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at [email protected].
- For any urgent concerns or inquiries, please contact us at [email protected].
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to [email protected] for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner